A new paper: Rapamycin seems to have the best performance (in this study) against lung cancer.
Conclusion:
Rapamycin is an mTORC1 inhibitor which affect the cell proliferation, mRNA transcription and protein synthesis. In this study, it was observed that rapamycin showed different level of cytotoxicity towards different cancer cell lines. Among the other cancer cell lines, rapamycin showed higher cytotoxicity to lung cancer cell line. In-silico analysis was performed to identify the reason behind the higher cytotoxicity of rapamycin on lung cancer (A549 cancer cell line). For the first time, the current study reported that rapamycin has a binding affinity with ALK, EGFR, FGFR, MET, and ROS1 receptors expressed in the lung cancer cells. Using RMSF simulation analysis, rapamycin was found to be more stable in ALK, EGFR and MET than other receptors. Binding of rapamycin with these over expressed receptors in the lung cancer will increase the cytotoxic effect in the A549 lung cancer cell line. In the current study, it was found that rapamycin can bind with receptors other than mTORC1 and carry out different functions.
Rapamycin is a versatile drug against different disorders like cancer and neurodegenerative abnormality. However, the mechanism by which rapamycin maintains the haemostasis in cancer and neurodegenerative disease is unclear. The current study states that rapamycin can bind with multiple receptors with in the same cell.
Open Access Paper: